| 1. |
NCCN. The NCCN esophageal and esophagogastric junction cancers clinical practice guidelines in oncology (version 1.2018). Fort Washington: NCCN, 2018. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
|
| 2. |
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 2006, 24(31): 4991-4997.
|
| 3. |
Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase Ⅲ trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol, 2007, 25(22): 3210-3216.
|
| 4. |
Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase Ⅲ trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 2007, 25(22): 3205-3209.
|
| 5. |
Overman MJ, Kazmi SM, Jhamb J, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer, 2010, 116(6): 1446-1453.
|
| 6. |
Tebbutt NC, Cummins MM, Sourjina T, et al. Randomised, non-comparative phase Ⅱ study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer, 2010, 102(3): 475-481.
|
| 7. |
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358(1): 36-46.
|
| 8. |
Al-Batran SE, Hartmann JT, Probst S, et al. Phase Ⅲ trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 2008, 26(9): 1435-1442.
|
| 9. |
Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase Ⅱ trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 2004, 22(4): 658-663.
|
| 10. |
Al-Batran SE, Kerber A, Atmaca A, et al. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie, 2007, 30(1-2): 29-34.
|
| 11. |
Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 2008, 19(11): 1882-1887.
|
| 12. |
Ilson DH. Phase Ⅱ trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park), 2004, 18(14 Suppl 14): 22-25.
|
| 13. |
Dank M, Zaluski J, Barone C, et al. Randomized phase Ⅲ study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol, 2008, 19(8): 1450-1457.
|
| 14. |
Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase Ⅱ trial. Anticancer Drugs, 2009, 20(3): 165-173.
|
| 15. |
Burtness B, Gibson M, Egleston B, et al. Phase Ⅱ trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol, 2009, 20(7): 1242-1248.
|
| 16. |
Lustberg MB, Bekaii-Saab T, Young D, et al. Phase Ⅱ randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol, 2010, 5(5): 713-718.
|
| 17. |
Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase Ⅱ study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol, 2010, 21(1): 71-77.
|
| 18. |
Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase Ⅲ study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol, 2014, 32(31): 3520-3526.
|
